Lenzing's Heiligenkreuz Reprieve and a Halved Target Price Put Execution in the Spotlight

Lenzing has bought itself a few extra months at Heiligenkreuz. On 22 October a company spokesperson confirmed to APA that the planned closure of the site will now take place in the first quarter of 2027 rather than at the end of 2026, with the group citing the transfer of production to other locations as the reason. Roughly 285 employees are affected by the shutdown — and roughly 30 interested parties have been in talks with Lenzing about a possible takeover of the plant, according to the company itself. Those discussions are an option, not an outcome.

The delay is neither proof that the restructuring has failed nor an all-clear. What it does show is that announcing a cutback and carrying it out are two different things, and that investors should keep a formulated savings target separate from improvements actually delivered.

A fresh EUR 301.2 million, and a target price cut in half

The capital increase completed a little over a week ago grossed Lenzing around EUR 301.2 million. New shares were placed at EUR 8.65 apiece, with existing shareholders taking up 99.0% of the offer. That is a substantial financing step rather than a mere stock-market signal — but it does not amount to an operational turnaround. A capital measure answers the question of additional equity; whether the restructuring delivers the intended economic gains has to be demonstrated separately. Anyone who conflates the two is declaring an important interim step the success of the entire transformation.

Deutsche Bank's assessment, reported yesterday, captured exactly that tension. The research house cut its price target to EUR 12.70 from EUR 22.00 while leaving its "Hold" rating unchanged, and analyst Lars vom Cleff simultaneously gave the transformation initiative a positive write-up. Endorsing the measures is not the same as endorsing the valuation: a restructuring can make sense while expectations for the stock still fall. The initiative that drew the positive note comprises additional savings of EUR 120 million and an targeted EBITDA increase of around EUR 150 million — figures that describe the programme's potential, not an earnings improvement already on the books.

The share price has been volatile around the news. It gained 7.4% yesterday, and was up 6.9% at EUR 10.62 in the session covered by the second report. Neither move is evidence of progress on the transformation; it is a snapshot of market reaction.

Should investors sell immediately? Or is it worth buying Lenzing?

Ownership filings describe the register, not the business

The corrected voting-rights notification published today also merits attention. Goldman Sachs Group reached a total of 5.86% of voting rights on Friday, up from 4.01% previously. The reported position includes financial instruments alongside shares, so it should not be read as direct stock ownership in full. Nor is a larger reported stake a buy recommendation from Goldman Sachs or proof that the transformation is working.

Following registration of the capital increase on 22 October, the syndicate continues to hold 52.25% of voting rights. The syndicate members' participation in the rights issue and their continuing majority describe the ownership structure; on their own they do not demonstrate higher operating profitability.

The margin is the yardstick

At the heart of the plan sits a targeted EBITDA margin of 20–25%. That range is the clearest measure of the operational ambition — and it describes an intended result, not a state already reached. The EUR 120 million in additional savings and the roughly EUR 150 million EBITDA uplift cover different aspects of the same effort: the planned cost contribution and the expected earnings improvement. Neither should be treated as relief already realised.

The counterargument carries real weight: Lenzing has posted net losses since 2022. A targeted EBITDA improvement does not automatically answer the question of a positive net result, and it would go too far to equate operating targets with a completed earnings turnaround. The negative scenario is a transformation whose earnings impact falls short of the goals — in which case the lower valuation implied by Deutsche Bank would carry more weight than its fundamentally positive view of the restart. An unchanged Hold rating, after all, cannot be read as unqualified confidence in a swift reversal.

What would settle the argument

Lenzing plans to publish third-quarter 2026 results on 5 November. That date gives investors a chance to set operating performance alongside the transformation plans. Not every effect of the restructuring needs to be visible by then; what matters is whether the disclosures allow a defensible reading of progress.

A convincing signal would be an earnings improvement that visibly narrows the distance to the targeted margin, or a solid company announcement on savings achieved and their earnings impact — with a clear distinction between targets reaffirmed once again and progress already made. The size of the announced improvement alone counts for little; the proof that Lenzing is getting closer to it counts for a great deal.

Ad

Lenzing Stock: New Analysis - 29 October

Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Lenzing analysis...